Spina bifida echocardiography and ultrasound

Jump to navigation Jump to search

Spina bifida Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Spina Bifida from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electroencephalogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Spina bifida echocardiography and ultrasound On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Spina bifida echocardiography and ultrasound

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Spina bifida echocardiography and ultrasound

CDC on Spina bifida echocardiography and ultrasound

Spina bifida echocardiography and ultrasound in the news

Blogs on Spina bifida echocardiography and ultrasound

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Spina bifida echocardiography and ultrasound

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Compared with the general population, the prevalence of congenital heart disease in newborns with myelomeningocele is increased , however critical disease is uncommon. When the myelomeningocele is prenatally diagnosed, antenatal cardiac screening is complete and normal, and the newborn is clinically well, preoperative echocardiography is unnecessary. Ultrasound is the imaging modality of choice for characterisation of the open spina bifida spinal lesions. On two and tree-dimensional ultrasound, spina bifida is characterized by: Vertebral defect, splayed vertebral pedicles and disrupted vertebrae. The ultrasound must be performed when a positive alpha-fetoprotein is detected in the triple screening test between the 15th and 20th week of pregnancy to confirm the diagnosis.

Echocardiography

  • Compared with the general population, the prevalence of congenital heart disease in newborns with myelomeningocele is increased , however critical disease is uncommon.[1]
  • When the myelomeningocele is prenatally diagnosed, antenatal cardiac screening is complete and normal, and the newborn is clinically well, preoperative echocardiography is unnecessary.[1]

Ultrasound

  • Ultrasound is the imaging modality of choice for characterisation of the open spina bifida spinal lesions.[2]
  • On two and tree-dimensional ultrasound, spina bifida is characterized by:[3]
Sequence of Diagnostic Studies

The ultrasound must be performed when a positive alpha-fetoprotein is detected in the triple screening test between the 15th and 20th week of pregnancy to confirm the diagnosis.[4][5][6][7]

References

  1. 1.0 1.1 Horobin RW (November 1971). "Analysis and purification of biological stains by gel filtration". Stain Technol. 46 (6): 297–304. PMID 5115780.
  2. Trudell AS, Odibo AO (April 2014). "Diagnosis of spina bifida on ultrasound: always termination?". Best Pract Res Clin Obstet Gynaecol. 28 (3): 367–77. doi:10.1016/j.bpobgyn.2013.10.006. PMID 24373566.
  3. Lee W, Chaiworapongsa T, Romero R, Williams R, McNie B, Johnson A, Treadwell M, Comstock CH (June 2002). "A diagnostic approach for the evaluation of spina bifida by three-dimensional ultrasonography". J Ultrasound Med. 21 (6): 619–26. PMID 12054297.
  4. Péron FG, McCarthy JL, Guerra F (April 1966). "Further studies on corticosteroidogenesis. IV. Inhibition of utilization of biological substrates for corticoid synthesis by high calcium concentrations. Possible role of transhydrogenase in corticosteroidogenesis". Biochim. Biophys. Acta. 117 (2): 450–69. PMID 4381295.
  5. Hu Z, Liu X, Li L, Jia C, Li D, Liu R (October 2014). "[Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes]". Zhonghua Fu Chan Ke Za Zhi (in Chinese). 49 (10): 749–53. PMID 25537246.
  6. Wyshak G, Haase JV (November 1976). "Profile of dental hygienists". Dent Hyg (Chic). 50 (11): 497–501. PMID 1071059.
  7. Shcherbukhin VV, Khramtsov AV, Zemskov VM, Filatov AV (April 1987). "[Poisson equalization of multicomponent cytofluorograms]". Tsitologiia (in Russian). 29 (4): 497–502. PMID 3111043.

Template:WH Template:WS